Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety follow-up of radium-223 dichloride
2014-002407-25Phase 4Completed
- Sponsor
- Bayer
- Start
- Oct 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, open-label trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), prostate cancer (PCa), breast cancer and 1 more (2 arms), sponsored by Bayer. Primary endpoint: Incidence and severity of radium-223 dichloride/placebo-related adverse events. Started Oct 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)prostate cancer (PCa)breast cancermultiple myeloma (MM)
Beyond the preview
Go deeper on 2014-002407-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002407-25.